<DOC>
	<DOCNO>NCT01013610</DOCNO>
	<brief_summary>To evaluate safety , tolerability , multiple dose plasma pharmacokinetics ( PK ) LNK-754 male female elderly volunteer dose LNK-754 7 day subject mild Alzheimer 's Disease dose LNK-754 28 day .</brief_summary>
	<brief_title>An Escalating Dose Study Evaluate Safety , Tolerability Pharmacokinetics LNK 754 Elderly Volunteers Subjects With Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Part A Part B : 1 . Males female age 60 year old . Females must surgically sterilize postmenopausal least two year . Males must actively practice doublebarrier contraception ( condom plus spermicide ) , unless vasectomy , partner ( ) meet criterion female . 2 . Voluntarily consent participate study provide write informed consent prior start studyspecific procedure . 3 . Be prepare adhere protocol requirement willing able remain study unit entire duration confinement period . They must also willing return EndofStudy Visit one week last dosing . Part A : 4 . Subjects must generally healthy , may enrol stable , chronic illness , well control interfere primary objective study . Subjects may include clinical deviation normal limit medical history , physical examination , vital sign measurement , ECG , laboratory test result associate stable , well control chronic illness . Subjects concomitant disease use concomitant medication allow participate provide stable condition stable treatment 1 month ( 30 day ) prior administration first dose study medication . Inclusion subject review Link Medical Monitor prior enrollment trial . Part B : 5 . Subjects Mild Alzheimer 's Disease , define DSMIV . 6 . Subjects score ≥ 1826 MiniMental State Examination ( MMSE ) . 7 . Subjects Clinical Dementia Rating ( CDR ) total score 0.5 1.0 ( possible mild dementia ) . 8 . Subjects RosenModified Hachinski Ischemic score ≤ 4 . Part A Part B : 1 . Any significant unstable uncontrolled cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease , determine medical history , physical examination laboratory test . 2 . Subjects positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . 3 . Subjects receive experimental drug device within 30 day prior dose wish receive experimental drug within 30 day complete study . 4 . Subjects unable understand protocol requirement , instruction study relate restriction , nature , scope possible consequence clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Healthy Elderly Volunteers</keyword>
</DOC>